Translating statistical findings into plain English

The Lancet

Volumn 373, Issue 9679, 2009, Pages 1926-1928

  Pocock, Stuart J ^a   Ware, James H ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; EVEROLIMUS; LOSARTAN; PLACEBO;

ARTICLE; CANCER SURVIVAL; CLINICAL RESEARCH; DRUG EFFICACY; KIDNEY CARCINOMA; LANGUAGE; MEDICAL INFORMATION; MEDICAL LITERATURE; PRIORITY JOURNAL;

EID: 66149190550     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60499-2     Document Type: Note

References (12)

1. Motzer R.J., Escudier B., Oudard S., et al., for the RECORD-1 Study Group. Efficacy of everolimus in advanced renal-cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008) 449-456
2. Dahlof B., Devereux R.B., Kjeldsen S.E., et al., for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
3. Bulpitt C.J. Confidence intervals. Lancet 1 (1987) 494-497
4. Calverley P., Anderson J.A., Celli B., et al., for the TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
5. Sterne J., and Davey Smith G. Sifting the evidence-what's wrong with significance tests?. BMJ 322 (2001) 226-231
6. Piaggio G., Elbourne D.R., Altman D.G., Pocock S.J., Evans S.J.W., and for the CONSORT Group. Reporting of non-inferiority and equivalence trials: an extension fo the CONSORT Statement. JAMA 295 (2006) 1152-1160
7. Windecker S., Serruys P.W., Wandel S., et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisations (LEADERS): a randomised non-inferiority trial. Lancet 372 (2008) 1163-1173
8. Abdulla S., Sagara I., Borrmann S., et al. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 372 (2008) 1819-1827
9. Sacco R.L., Diener H.-C., Yusuf S., et al., for the PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 358 (2008) 1238-1251
10. Wang R., Lagakos S.W., Ware J.H., et al. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 357 (2007) 2189-2194
11. Fox K., Ford I., Steg P.G., et al., on behalf of the BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 807-816
12. Pocock S.J., and Elbourne D.R. Randomised trials or observational tribulations?. N Engl J Med 342 (2000) 1907-1909